BioCentury | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

...receptor subfamily C member 1 Sandi Wong, Staff Writer monalizumab (NN8765-3658, iph2201, Anti-NKG2a, IPH 2201, IPH22XX) IPH4102 IPH5401 Innate Pharma S.A. CD22 Killer cell lectin-like receptor subfamily C member 1 (NKG2A) (CD159a) (KLRC1) Killer...
BioCentury | Oct 26, 2018
Company News

AstraZeneca gets rights, options to Innate immuno-oncology therapies

...NN8765-3658, iph2201, Anti-NKG2a, IPH 2201, IPH22XX) AstraZeneca plc Innate Pharma S.A. Novo Nordisk A/S CD22 Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) (ENTPD1) Killer cell lectin-like receptor subfamily C member 1 (NKG2A) (CD159a) (KLRC1) IPH5201...
BioCentury | Oct 23, 2018
Company News

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

...CAT-8015 ) monalizumab (NN8765-3658, iph2201, Anti-NKG2a, IPH 2201, IPH22XX) AstraZeneca plc Innate Pharma S.A. CD22 Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) (ENTPD1) Killer cell lectin-like receptor subfamily C member 1 (NKG2A) (CD159a) (KLRC1) immuno-metabolism IPH5201 NK...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...Innovations (2018) Martz, L. “Innate Harmony.” BioCentury Innovations (2016) Lauren Martz, Senior Writer Innate Pharma S.A. Oxford BioTherapeutics Ltd. Killer cell lectin-like receptor subfamily C member 1 (NKG2A) (CD159a) (KLRC1) Killer...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
BioCentury | Jun 1, 2018
Clinical News

Innate reports Phase I data for monalizumab plus Imfinzi in CRC

...MEDI4736) monalizumab (NN8765-3658, iph2201, Anti-NKG2a, IPH 2201, IPH22XX) American Society of Clinical Oncology ASCO AstraZeneca plc Innate Pharma S.A. Novo Nordisk A/S Killer cell lectin-like receptor subfamily C member 1 (NKG2A) (CD159a) (KLRC1) Programmed...
BioCentury | May 9, 2018
Translation in Brief

The fate of NK cells

...Writer Fate Therapeutics Inc. University of Oslo CD19 CD57 Killer cell immunoglobulin-like receptors (KIRs) Killer cell lectin like receptor 2 (KLRC2) (NKG2C) Killer cell lectin-like receptor subfamily C member 1 (NKG2A) (CD159a) (KLRC1)...
Items per page:
1 - 7 of 7